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been identified by non-targeted approaches, such as
comprehensive DNase-hypersensitivity-site or chroma-
tin immunoprecipitation assays. Thus, an unbiased
search of the Ifng locus may identify important regula-
tory elements in addition to those that have now been
identified.
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693Peptides Made to Order
How loading of major histocompatibility complex
(MHC) class I-specific peptides by conserved degra-
dation machinery is performed economically has
now been resolved by Kanaseki et al. (2006) in this
issue of Immunity: The individual MHC molecule
serves as a template for its own ligand.
MHC class I molecules, the peptide receptors that sam-
ple cellular protein-degradation products for display on
the surface, are of exceptional specificity. Their ligands
are peptides of defined lengths—9 amino acids in most
cases—and have certain sequence characteristics that
are summarized as motifs (Falk et al., 1991). MHC genes
exhibit a remarkable polymorphism; for the human MHC
class I genes (human leukocyte antigen [HLA]-A, B, and
C), for example, around 1500 different alleles are known
to date, and each allelic product has its own distinct
peptide-receptor specificity. This polymorphism pro-
vides powerful protection within a host population
against attempts by intracellular pathogens to escape
immune recognition.
In sharp contrast to the polymorphic MHC genes, the
components of antigen processing are very conserved
(Pamer and Cresswell, 1998). Thus, we run into a conun-
drum. How can the protein-degradation machinery of
the cell provide peptides with specificity for so many
different MHC molecules? Does the degradation ma-
chinery generate all possible permutations of size and
specificity from each protein molecule? Early experi-
ments indicate that such preformed peptides cannot
be found in a cell unless the fitting MHC molecule
is coexpressed (Falk et al., 1990). This led to the hypoth-
esis that MHC I molecules themselves may serve astemplates for shaping their own ligands. An alternative
explanation, however, would be that all peptide permu-
tations are produced and only the ones that are pro-
tected from further degradation by binding to an MHC
molecule are degraded further, and so rapidly that they
remain undetectable experimentally.
We now have a better understanding of how the con-
served protein-degradation machinery can serve all
existing MHC I molecules. It is a process consisting of
several steps. The last step is, however, the most so-
phisticated one, as Kanaseki et al. (2006) demonstrate.
Let us now follow the main protein-degradation path-
way for MHC I loading step-by-step (see Figure 1). First,
we have the cleavage of ubiquitinated protein by the
proteasome. The proteasome cleaves proteins into
peptides of roughly 5–20 amino acids (aa), mostly with
hydrophobic or basic C termini, which, as far as we
know, are preferred by mammalian MHC binding
pockets (Stevanovic, 2005). Thus, the C termini of the
peptides leaving the proteasome already constitute
the C termini of the final MHC ligands. Peptides are
now attacked by cytosolic aminopeptidases such as
bleomycin hydrolase or puromycin-sensitive amino
peptidase (Stoltze et al., 2000). The latter have also re-
cently been shown to have some specificity for serving
MHC I molecules; they tend to spare those N-terminal
amino acids that are favored by the following step,
which is the transport of peptides by the transporter as-
sociated with antigen processing (TAP) into the endo-
plasmatic reticulum (ER) lumen (M. Schatz and H.
Schild, personal communication). TAP has a specificity
for a certain peptide length, for hydrophobic and, for
humans, also for basic C termini. Once they arrive in
the ER lumen, the peptides are attacked by luminal ami-
nopeptidases, ERAAP I and ERAAP II, and eventually
destroyed completely if not protected by binding to an
MHC molecule (Serwold et al., 2002; Saric et al., 2002;
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694Figure 1. Protein-Degradation Pathway Lead-
ing to MHC Class I Loading
In the cytosol, proteins are degraded by the
proteasome. Most of the resulting peptides
possess C termini required by MHC I mole-
cules. Peptides of various lengths are trans-
ported by the peptide transporter, TAP, from
the cytosol to the ER lumen. There, peptides
will have one of three fates: (1) Peptides that
happen to contain a fitting MHC I motif and
to be of the correct length bind to one of the
newly synthezised MHC I molecules; (2) pep-
tides with a proper MHC I motif, but still too
long on their N terminus, do bind to MHC
molecules and are then trimmed by ERAAP,
whereby the superfluous amino acids at the
N terminus are cut away; and (3) peptides
not containing a fitting motif are completely
degraded by ERAAP. MHC I molecules
successfully loaded are exported to the cell
surface. Several molecules involved in MHC
I assembly, such as Tapasin or ERp57, have
been omitted for clarity.York et al., 2006). Thus, the general assumption until
now has been that at this step of processing, a peptide
that happens to reach the appropriate length of 9 aa
(or 8, 10, or 11 aa) is protected by binding to an MHC
molecule if the remaining part of the motif also happens
to fit. This still implies that a large collection of 8, 9, 10,
or 11 mers have to be preformed, from which MHC mol-
ecules pick out only very few, and that all the peptides
should be available for a timespan long enough to allow
chance collision with all the MHC molecules at hand to
occur. Stoichiometrically, this scenario appears very
unlikely considering that thousands of different proteins
are processed simultaneously and that six different
MHC molecules (e.g., two allelic products each of
HLA-A, B, and C) are lining up in the ER to find peptides.
Kanaseki and colleagues from the Shastri lab now
reveal that our cells have a smart solution: Peptides
entering the ER via TAP bind to MHC molecules imme-
diately, as long as the C terminus is correct and the ap-
propriate motif is present. At this stage, the length is not
yet crucial. Now, with the part of the peptide later corre-
sponding to the ligand in the MHC groove, the superflu-
ous N-terminal amino acids are removed by ER amino-
peptidase associated with antigen processing (ERAAP).
Thus, all peptides not possessing the correct C termi-
nus and the appropriate motif for the MHC molecules
at hand can be completely destroyed and no longer
compete for space in the local compartment. Thus,
stoichiometry is not a problem.
Kanaseki et al. (2006) carried out their experiments
with ERAAP-deficient mouse cells and cells reconsti-
tuted with functional or mutated ERAAP, together with
well-studied MHC I ligands such as the H2-Kb restricted
SIINFEKL peptide derived from ovalbumin or an H2-Ld
restricted peptide, QLSPFPFDL. Cells were transfected
with minigenes coding for N-terminally extended se-
quences of ligands. One series of experiments directly
shows the involvement of both ERAAP and the H2-Ld
molecule in making the 9 mer ligand. From cells ex-
pressing the N-terminally extended precursor se-
quence, but no functional ERAAP, the precursor peptide
of 13 amino acids can be isolated. In ERAAP-expressing
cells, however, the amount of this long peptide isdrastically reduced, indicating degradation of the 13
mer by ERAAP. Cells coexpressing ERAAP and H2-Ld
produced high amounts of the final 9 mer ligand,
whereas cells lacking H2-Ld contained only minute
amounts of this ligand. Their key experiment was then
to precipitate an H2-Ld molecule carrying a precursor
peptide. It was only possible to identify these MHC I-
bound precursors by a sophisticated experimental de-
sign where the precursor was eluted from H2-Ld and
the ligand was freed by trypsin digestion and subse-
quently detected by T cells.
Thus, the originally opposing hypotheses—trimming
on template versus protection of preformed peptides—
have found a common ground: MHC molecules selec-
tively bind suitable ligand precursors and protect them
from complete degradation, but have them trimmed by
ERAAP to give a perfect fit. The findings by Kanaseki
et al. (2006) appear to be at variance with a study on in
vitro activity of ERAAP (Chang et al., 2005). This study
proposes that ERAAP acts as a ‘‘molecular ruler’’ de-
grading free peptides until a length of 9 aa is reached.
This ‘‘molecular ruler’’ model would not solve the stoi-
chiometric problem mentioned above and would not
explain the loading of 8 mers, 10 mers, or 11 mers onto
MHC I molecules. The present work by Kanaseki et al.
(2006) focuses on in vivo (cellular) experiments, and,
thus, the molecular-ruler model is not supported.
The findings by Kanaseki et al. (2006) raise further
questions in the field of antigen processing, T cell epi-
tope prediction, and vaccine design. First, the new find-
ings predict the physical contact between ERAAP and
MHC molecules, thereby extending the number of dif-
ferent parts involved in the peptide-loading complex
to at least eight polypeptides: MHC heavy chain, b2-mi-
croglobulin, TAP1, TAP2, tapasin, calreticulin, ERp57,
and now ERAAP.
The development of new, molecularly defined vac-
cines against viruses, intracellular bacteria, and, in par-
ticular, cancer, is assisted by the prediction and identi-
fication of T cell epitopes. One successful approach has
been to build a database of naturally presented MHC
ligands that have passed all the steps of antigen
processing and to use this database for predicting
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695new ligands. Newer approaches aim to dissect the re-
quirements for each step of antigen processing—that
is, proteasome cleavage specificity, TAP specificity,
and MHC binding specificity (reviewed in Stevanovic
[2005]). Such approaches should now consider ERAAP
activity on MHC-bound peptides when determining
criteria for epitope generation.
Hans-Georg Rammensee1
1Department of Immunology
University of Tu¨bingen
D-72076 Tu¨bingen
Germany
Selected Reading
Chang, S.C., Momburg, F., Bhutani, N., and Goldberg, A.L. (2005).
Proc. Natl. Acad. Sci. USA 102, 17107–17112.Immunity 25, November 2006 ª2006 Elsevier Inc. DOI 10.1016/j.immuni.2006
Human Tyk2 Kinase Deficiency:
Another Primary
Immunodeficiency Syndrome
Janus kinases are critical for cytokine signaling. Muta-
tions of Jak3 cause primary immunodeficiency, but
Minegishi et al. (2006) now show that mutation of an-
other Jak, tyrosine kinase 2, underlies another human
immunodeficiency syndrome.
Cytokines regulate immune-cell development, homeo-
stasis, differentiation, and effector function; as such,
they have critical roles in host defense and in the path-
ogenesis of autoimmune and autoinflammatory disor-
ders. A large subset of cytokine receptors (type I and
II cytokine receptors) lack intrinsic kinase activity, but
instead rely on a small family of receptor-associated
cytoplasmic tyrosine kinases to initiate signaling. This
family, known as Janus kinases or Jaks, consists of only
four members, Jaks1–3 and tyrosine kinase 2 (Tyk2).
The essential function of Jaks in effecting cytokine sig-
nals has been substantiated by various approaches and
is underscored by the fact that Jak3 mutations result in
severe combined immunodeficiency (SCID) in humans.
Other Jaks were not previously associated with primary
immunodeficiency in humans, but Tyk2 can now be
added to the list. Minegishi et al. (2006) have identified
a patient with Tyk2 deficiency who exhibited broader
and more profound immunological defects than would
be anticipated from studies of Tyk22/2mice. The signal-
ing defects resulted in a complex clinical picture that
included Hyper IgE Syndrome (HIES) and susceptibility
to multiple infectious pathogens.Falk, K., Rotzschke, O., and Rammensee, H.G. (1990). Nature 348,
248–251.
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Jaks constitutively associate with the cytoplasmic
domains of type I and II cytokine receptors and, upon
ligand binding, phosphorylate receptor subunits. This
serves to recruit signal transducers and activators of
transcription (Stats) and other adapters and signaling
molecules. Jaks also phosphorylate and activate Stats,
promoting nuclear translocation and transcription. The
connection between Jaks and cytokine signaling was
first revealed when a screen for genes involved in type
I interferon (IFN) signaling identified Tyk2 as an essen-
tial element (Velazquez et al., 1992). Shortly thereafter,
through the use of somatic mutant cell lines, the first de-
fined connections between different cytokine receptors
and different Jaks and Stats were made (Darnell et al.,
1994). In vitro stimulations also paired different Jaks
with apparent activating cytokines.
The first in vivo proof that Jaks are critical for cytokine
signaling came from studies of a group of human disor-
ders termed SCID. Jak3 selectively associates with the
common g cytokine receptor chain (gc), and mutations
in gc were known to cause SCID (X-SCID). Mutations
of JAK3 were therefore sought and found to underlie
some cases of autosomal recessive SCID (Macchi
et al., 1995); a similar phenotype was also observed in
Jak3-deficient mice. Several years later, Jak1- and
Jak2-deficient mice were produced, but it was not until
2000 that Tyk2-deficient mice were generated (Kara-
ghiosoff et al., 2000; Shimoda et al., 2000). In contrast
to Jak3, which appears to associate with only one re-
ceptor subunit, Tyk2 is activated by an array of cytokine
receptors. It was therefore striking that Tyk2 deficiency
in mice identified somewhat limited roles for this kinase,
primarily in interleukin 12 (IL-12) and interferon (IFN-)
a and b signaling.
In a compelling new study, Minegishi et al. (2006)
identified a patient homozygous for a TYK2 mutation
